Targeting P-selectin and interleukin-1β in mice with sickle cell disease: effects on vaso-occlusion, liver injury and organ iron deposition.

IF 8.2 1区 医学 Q1 HEMATOLOGY
Érica M F Gotardo, Lidiane S Torres, Bruna Cunha Zaidan, Lucas F S Gushiken, Pâmela L Brito, Flavia C Leonardo, Claudia H Pellizzon, John Millholland, Sergei Agoulnik, Jiri Kovarik, Fernando F Costa, Nicola Conran
{"title":"Targeting P-selectin and interleukin-1β in mice with sickle cell disease: effects on vaso-occlusion, liver injury and organ iron deposition.","authors":"Érica M F Gotardo, Lidiane S Torres, Bruna Cunha Zaidan, Lucas F S Gushiken, Pâmela L Brito, Flavia C Leonardo, Claudia H Pellizzon, John Millholland, Sergei Agoulnik, Jiri Kovarik, Fernando F Costa, Nicola Conran","doi":"10.3324/haematol.2024.286418","DOIUrl":null,"url":null,"abstract":"<p><p>Continuous vaso-occlusive and inflammatory processes cause extensive end-organ damage in adults with sickle cell disease (SCD), and there is little evidence that longterm hydroxyurea therapy prevents this. In initial trials, P-selectin blockade with crizanlizumab reduced SCD vaso-occlusive crisis frequency, and interleukin (IL)-1β inhibition in SCD patients, using canakinumab, lowered inflammatory markers. We used murine SCD models to examine the effects of acute and chronic blockade of Pselectin and of IL-1β on vaso-occlusive events, their inflammatory profile and organ health. Both approaches improved impaired cutaneous microvascular perfusion in SCD mice by reducing TNF-α-induced vaso-occlusion. Acute P-selectin blockade markedly reduced TNF-α-induced neutrophil-platelet aggregate formation in SCD mice, and decreased leukocyte-rolling movements in the microvasculature, while acute IL-1β inhibition attenuated microvascular leukocyte adhesion. Six weeks of IL-1β-blocking immunotherapy improved the inflammatory profile of SCD mice, considerably reduced hepatic fibrosis and provided some relief from lung injury. In contrast, although Pselectin blockade reduced glomerular congestion, no significant benefit to overall organ pathology was observed. Unexpectedly, while combining the two immunotherapies reduced microvascular occlusion, their prolonged use caused acute liver injury. Notably, inhibition of IL-1β, but not of P-selectin, remarkably decreased hemosiderosis, in association with reduced tissue macrophage infiltration and the correction of biomarkers of dysregulated iron turnover. Our findings suggest that the attenuation of inflammation, as well as of vaso-occlusive processes, may be crucial for mitigating organ damage in SCD. Future trials should explore the ability of cytokine blockade to prevent multiorgan damage in patients with SCD, beyond evaluating vaso-occlusive crisis frequency.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3324/haematol.2024.286418","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Continuous vaso-occlusive and inflammatory processes cause extensive end-organ damage in adults with sickle cell disease (SCD), and there is little evidence that longterm hydroxyurea therapy prevents this. In initial trials, P-selectin blockade with crizanlizumab reduced SCD vaso-occlusive crisis frequency, and interleukin (IL)-1β inhibition in SCD patients, using canakinumab, lowered inflammatory markers. We used murine SCD models to examine the effects of acute and chronic blockade of Pselectin and of IL-1β on vaso-occlusive events, their inflammatory profile and organ health. Both approaches improved impaired cutaneous microvascular perfusion in SCD mice by reducing TNF-α-induced vaso-occlusion. Acute P-selectin blockade markedly reduced TNF-α-induced neutrophil-platelet aggregate formation in SCD mice, and decreased leukocyte-rolling movements in the microvasculature, while acute IL-1β inhibition attenuated microvascular leukocyte adhesion. Six weeks of IL-1β-blocking immunotherapy improved the inflammatory profile of SCD mice, considerably reduced hepatic fibrosis and provided some relief from lung injury. In contrast, although Pselectin blockade reduced glomerular congestion, no significant benefit to overall organ pathology was observed. Unexpectedly, while combining the two immunotherapies reduced microvascular occlusion, their prolonged use caused acute liver injury. Notably, inhibition of IL-1β, but not of P-selectin, remarkably decreased hemosiderosis, in association with reduced tissue macrophage infiltration and the correction of biomarkers of dysregulated iron turnover. Our findings suggest that the attenuation of inflammation, as well as of vaso-occlusive processes, may be crucial for mitigating organ damage in SCD. Future trials should explore the ability of cytokine blockade to prevent multiorgan damage in patients with SCD, beyond evaluating vaso-occlusive crisis frequency.

针对镰状细胞病小鼠的 P 选择素和白细胞介素-1β:对血管闭塞、肝损伤和器官铁沉积的影响。
持续的血管闭塞和炎症过程会对成人镰状细胞病(SCD)患者的内脏器官造成广泛损伤,但几乎没有证据表明长期羟基脲疗法可以预防这种损伤。在最初的试验中,克利珠单抗(crizanlizumab)阻断P-选择素(P-selectin)可降低SCD血管闭塞危象的发生频率,卡那单抗(canakinumab)抑制白细胞介素(IL)-1β可降低SCD患者的炎症指标。我们利用小鼠 SCD 模型研究了急性和慢性阻断 Pselectin 和 IL-1β 对血管闭塞事件、其炎症特征和器官健康的影响。通过减少 TNF-α 诱导的血管闭塞,这两种方法都改善了 SCD 小鼠受损的皮肤微血管灌注。急性P-选择素阻断可显著减少TNF-α诱导的SCD小鼠中性粒细胞-血小板聚集形成,并减少微血管中的白细胞滚动运动,而急性IL-1β抑制可减轻微血管白细胞粘附。为期六周的 IL-1β 阻断免疫疗法改善了 SCD 小鼠的炎症特征,大大减轻了肝纤维化,并在一定程度上缓解了肺损伤。与此相反,虽然 Pselectin 阻断剂减轻了肾小球充血,但对整体器官病理却无明显益处。意想不到的是,虽然两种免疫疗法联合使用可减少微血管闭塞,但长期使用会造成急性肝损伤。值得注意的是,抑制 IL-1β(而非 P-选择素)可显著减少血丝沉着,这与组织巨噬细胞浸润减少以及铁代谢失调的生物标志物得到纠正有关。我们的研究结果表明,减轻炎症和血管闭塞过程可能是减轻 SCD 器官损伤的关键。未来的试验除了评估血管闭塞危象的发生频率外,还应该探索细胞因子阻断预防 SCD 患者多器官损伤的能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Haematologica
Haematologica 医学-血液学
CiteScore
14.10
自引率
2.00%
发文量
349
审稿时长
3-6 weeks
期刊介绍: Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信